ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Causes of Death Due to Hematological and Non-Hematological Cancers in 57 US Patients with Type 1 Gaucher Disease Who Were Never Treated with Enzyme Replacement Therapy

巻 18, 発行 3, 2013, pp. 177-195
DOI: 10.1615/CritRevOncog.2013005921
Get accessGet access

要約

Patients with type 1 Gaucher disease (GD1) have increased risk of developing myeloma, other hematological cancers, hepatocellular carcinoma, and other solid tumors. Patient awareness of the GD1–cancer association causes anxiety and fear. Little is known about cancer as a cause of death in GD1, especially in patients never treated with GD1-specific therapies. Consequently, the effect of treatment on cancer mortality in GD1 patients is difficult to evaluate. In this review, starting with a population of 184 GD1 cases never treated, we annotate and analyze the causes of death of 57 GD1 patients who died of cancer. The proportional mortality ratio (PMR) for all malignancies in patients with GD1 is 1.57 (p = 0.0002), but it is much higher for myeloma (PMR = 9.66) and other hematological cancers, hepatocellular carcinoma, and kidney cancer (PMR = ≈4). However, deaths from colorectal and pancreatic cancers were not more frequent than expected, and deaths from lung, breast, gynecological, and prostate cancer occurred less than anticipated. Herein, we discuss whether GD1 is truly a hereditary cancer syndrome and the problem of comorbidities and cancer risk assessment, and we speculate as to whether the variability in death by cancer type might be attributable to biochemical sequelae of tumor cell and macrophage/stromal cell GBA1 mutation affecting signals for metastasis, the process most closely associated with cancer mortality.

によって引用された
  1. Pavlova Elena V, Archer Joy, Z Wang Susan, Dekker Nick, Aerts Johannes MFG, Karlsson Stefan, Cox Timothy M, Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy, The Journal of Pathology, 235, 1, 2015. Crossref

  2. Hollak Carla E. M., Wijburg Frits A., Treatment of lysosomal storage disorders: successes and challenges, Journal of Inherited Metabolic Disease, 37, 4, 2014. Crossref

  3. Siebert Marina, Sidransky Ellen, Westbroek Wendy, Glucocerebrosidase is shaking up the synucleinopathies, Brain, 137, 5, 2014. Crossref

  4. Cox Timothy M, Drelichman Guillermo, Cravo Renata, Balwani Manisha, Burrow Thomas Andrew, Martins Ana Maria, Lukina Elena, Rosenbloom Barry, Ross Leorah, Angell Jennifer, Puga Ana Cristina, Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial, The Lancet, 385, 9985, 2015. Crossref

  5. Weinreb Neal J., Finegold David N., Feingold Eleanor, Zeng Zhen, Rosenbloom Barry E., Shankar Suma P., Amato Dominick, Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3), Orphanet Journal of Rare Diseases, 10, 1, 2015. Crossref

  6. Cox T.M., Lysosomal Diseases, in Encyclopedia of Cell Biology, 2016. Crossref

  7. Weinreb Neal J., Kaplan Paige, The history and accomplishments of the ICGG Gaucher registry, American Journal of Hematology, 90, 2015. Crossref

  8. Utz Jeanine, Whitley Chester B., van Giersbergen Paul L.M., Kolb Stefan A., Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug–drug interactions, Molecular Genetics and Metabolism, 117, 2, 2016. Crossref

  9. Murugesan Vagishwari, Lischuk Andrew, Haims Andrew, Lackman Richard, Brooks John S., Mankin Henry, Mistry Pramod K., Case series and literature review of skeletal tumors and their incidence in the Gaucher disease population, American Journal of Hematology, 91, 7, 2016. Crossref

  10. Nalysnyk Luba, Rotella Philip, Simeone Jason C., Hamed Alaa, Weinreb Neal, Gaucher disease epidemiology and natural history: a comprehensive review of the literature, Hematology, 22, 2, 2017. Crossref

  11. Mistry Pramod K., Lopez Grisel, Schiffmann Raphael, Barton Norman W., Weinreb Neal J., Sidransky Ellen, Gaucher disease: Progress and ongoing challenges, Molecular Genetics and Metabolism, 120, 1-2, 2017. Crossref

  12. Regenboog Martine, Bohte Anneloes E., Somers Inne, van Delden Otto M., Maas Mario, Hollak Carla E.M., Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease, Blood Cells, Molecules, and Diseases, 60, 2016. Crossref

  13. Lal Tamanna Roshan, Borger Daniel K., Sidransky Ellen, Once again, rare diseases provide a spotlight, Molecular Genetics and Metabolism, 118, 1, 2016. Crossref

  14. Regenboog Martine, van Kuilenburg André B.P., Verheij Joanne, Swinkels Dorine W., Hollak Carla E.M., Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications, Blood Reviews, 30, 6, 2016. Crossref

  15. Hasiński Piotr, Bik-Multanowski Mirosław, Koba-Wszędobył Magdalena, Walczak Mieczysław, Bubnowski Marek, Milewska-Kranc Agnieszka, Smyk Andrzej, Machaczka Maciej, Choroba Gauchera – zalecenia dotyczące rozpoznawania, leczenia i monitorowania, Acta Haematologica Polonica, 48, 4, 2017. Crossref

  16. Regenboog Martine, Bohte Anneloes E., Akkerman Erik M., Stoker Jaap, Hollak Carla E.M., Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment, British Journal of Haematology, 179, 4, 2017. Crossref

  17. Regenboog Martine, van Dussen Laura, Verheij Joanne, Weinreb Neal J., Santosa David, vom Dahl Stephan, Häussinger Dieter, Müller Meike N., Canbay Ali, Rigoldi Miriam, Piperno Alberto, Dinur Tama, Zimran Ari, Mistry Pramod K., Salah Karima Yousfi, Belmatoug Nadia, Kuter David J., Hollak Carla E. M., Hepatocellular carcinoma in Gaucher disease: an international case series, Journal of Inherited Metabolic Disease, 41, 5, 2018. Crossref

  18. Gary Sam E., Ryan Emory, Steward Alta M., Sidransky Ellen, Recent advances in the diagnosis and management of Gaucher disease, Expert Review of Endocrinology & Metabolism, 13, 2, 2018. Crossref

  19. Degnan Andrew J., Ho-Fung Victor M., Ahrens-Nicklas Rebecca C., Barrera Christian A., Serai Suraj D., Wang Dah-Jyuu, Ficicioglu Can, Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement, Insights into Imaging, 10, 1, 2019. Crossref

  20. Kumar Ashish, Acharya Subrat K., Singh Shivaram P., Arora Anil, Dhiman Radha K., Aggarwal Rakesh, Anand Anil C., Bhangui Prashant, Chawla Yogesh K., Datta Gupta Siddhartha, Dixit Vinod K., Duseja Ajay, Kalra Naveen, Kar Premashish, Kulkarni Suyash S., Kumar Rakesh, Kumar Manoj, Madhavan Ram, Mohan Prasad V.G., Mukund Amar, Nagral Aabha, Panda Dipanjan, Paul Shashi B., Rao Padaki N., Rela Mohamed, Sahu Manoj K., Saraswat Vivek A., Shah Samir R., Shalimar , Sharma Praveen, Taneja Sunil, Wadhawan Manav, 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations, Journal of Clinical and Experimental Hepatology, 10, 1, 2020. Crossref

  21. Nair Shiny, Bar Noffar, Xu Mina L., Dhodapkar Madhav, Mistry Pramod K., Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy, Molecular Genetics and Metabolism, 129, 4, 2020. Crossref

  22. Carubbi Francesca, Cappellini Maria Domenica, Fargion Silvia, Fracanzani Anna Ludovica, Nascimbeni Fabio, Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist, Digestive and Liver Disease, 52, 4, 2020. Crossref

  23. Bonesteele Grant, Gargus J. Jay, Curtin Emily, Tang Mabel, Rosenbloom Barry, Kimonis Virginia, Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease, Molecular Genetics and Metabolism Reports, 25, 2020. Crossref

  24. van Dussen Laura, Biegstraaten Marieke, Dijkgraaf Marcel GW, Hollak Carla EM, Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications, Orphanet Journal of Rare Diseases, 9, 1, 2014. Crossref

  25. Adar Tomer, Ilan Yaron, Elstein Deborah, Zimran Ari, Liver involvement in Gaucher disease – Review and clinical approach, Blood Cells, Molecules, and Diseases, 68, 2018. Crossref

  26. Giraldo Pilar, Andrade-Campos Marcio, Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease, Journal of Blood Medicine, Volume 12, 2021. Crossref

  27. Weinreb Neal J, Barbouth Deborah S, Lee Robert E, Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy, Blood Cells, Molecules, and Diseases, 68, 2018. Crossref

  28. Cox Timothy M., Lysosomal Diseases, in Encyclopedia of Cell Biology, 2023. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain